Regulation of microglial survival and proliferation in health and diseases

Seminars in Immunology

Volumn 27, Issue 6, 2015, Pages 410-415

  Ulland, Tyler K ^a   Wang, Yaming ^a   Colonna, Marco ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's; CSF 1; CSF 1R; Glioblastoma; IL 34; Microglia; Neurodegeneration; TREM2

Indexed keywords

CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; DEGENERATIVE DISEASE; GENOMICS; GLIOBLASTOMA; HUMAN; MICROGLIA; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; REVIEW; ANIMAL; CENTRAL NERVOUS SYSTEM; CYTOLOGY; IMMUNOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; HUMANS; MICROGLIA; NEURODEGENERATIVE DISEASES;

EID: 84965179082     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2016.03.011     Document Type: Review

References (71)

1. Gomez Perdiguero E., Schulz C., Geissmann F. Development and homeostasis of resident myeloid cells: the case of the microglia. Glia 2013, 61:112-120.
2. Shemer A., Erny D., Jung S., Prinz M. Microglia plasticity during health and disease: an immunological perspective. Trends Immunol. 2015, 36:614-624.
3. Ginhoux F., Prinz M. Origin of microglia: current concepts and past controversies. Cold Spring Harb. Perspect. Biol. 2015, 7.
4. Waisman A., Ginhoux F., Greter M., Bruttger J. Homeostasis of microglia in the adult brain: review of novel microglia depletion systems. Trends Immunol. 2015, 36:625-636.
5. Kierdorf K., Erny D., Goldmann T., Sander V., Schulz C., Perdiguero E.G., et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci. 2013, 16:273-280.
6. Greter M., Lelios I., Pelczar P., Hoeffel G., Price J., Leboeuf M., et al. Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. Immunity 2012, 37:1050-1060.
7. Nandi S., Gokhan S., Dai X.M., Wei S., Enikolopov G., Lin H., et al. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev. Biol. 2012, 367:100-113.
8. Stanley E.R., Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb. Perspect. Biol. 2014, 6.
9. Wang Y., Szretter K.J., Vermi W., Gilfillan S., Rossini C., Cella M., et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of langerhans cells and microglia. Nat. Immunol. 2012, 13:753-760.
10. Wegiel J., Wisniewski H.M., Dziewiatkowski J., Tarnawski M., Kozielski R., Trenkner E., et al. Reduced number and altered morphology of microglial cells in colony stimulating factor-1-deficient osteopetrotic op/op mice. Brain Res. 1998, 804:135-139.
11. Tos M., Trojaborg N., Thomsen J. The contralateral ear after translabyrinthine removal of acoustic neuromas: is there a drill-noise generated hearing loss. J. Laryngol. Otol. 1989, 103:845-849.
12. Yeung Y.G., Wang Y., Einstein D.B., Lee P.S., Stanley E.R. Colony-stimulating factor-1 stimulates the formation of multimeric cytosolic complexes of signaling proteins and cytoskeletal components in macrophages. J. Biol. Chem. 1998, 273:17128-17137.
13. Lanier L.L., Corliss B.C., Wu J., Leong C., Phillips J.H. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998, 391:703-707.
14. Otero K., Turnbull I.R., Poliani P.L., Vermi W., Cerutti E., Aoshi T., et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat. Immunol. 2009, 10:734-743.
15. Bouchon A., Hernandez-Munain C., Cella M., Colonna M. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J. Exp. Med. 2001, 194:1111-1122.
16. Butovsky O., Jedrychowski M.P., Moore C.S., Cialic R., Lanser A.J., Gabriely G., et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat. Neurosci. 2014, 17:131-143.
17. Gosselin D., Link V.M., Romanoski C.E., Fonseca G.J., Eichenfield D.Z., Spann N.J., et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 2014, 159:1327-1340.
18. Atagi Y., Liu C.C., Painter M.M., Chen X.F., Verbeeck C., Zheng H., et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J. Biol. Chem. 2015.
19. Bailey C.C., DeVaux L.B., Farzan M. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J. Biol. Chem. 2015.
20. Guerreiro R., Bilgic B., Guven G., Bras J., Rohrer J., Lohmann E., et al. Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiol. Aging 2013, 34. 2890. e2891-e2895.
21. Guerreiro R.J., Lohmann E., Bras J.M., Gibbs J.R., Rohrer J.D., Gurunlian N., et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013, 70:78-84.
22. Kleinberger G., Yamanishi Y., Suarez-Calvet M., Czirr E., Lohmann E., Cuyvers E., et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 2014, 6. 243ra286.
23. Kiialainen A., Hovanes K., Paloneva J., Kopra O., Peltonen L. Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. Neurobiol. Dis. 2005, 18:314-322.
24. Nicholson A.M., Baker M.C., Finch N.A., Rutherford N.J., Wider C., Graff-Radford N.R., et al. CSF1R mutations link POLD and HDLS as a single disease entity. Neurology 2013, 80:1033-1040.
25. Numasawa Y., Yamaura C., Ishihara S., Shintani S., Yamazaki M., Tabunoki H., et al. Nasu-Hakola disease with a splicing mutation of TREM2 in a Japanese family. Eur. J. Neurol. 2011, 18:1179-1183.
26. Paloneva J., Manninen T., Christman G., Hovanes K., Mandelin J., Adolfsson R., et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 2002, 71:656-662.
27. Wang Y., Cella M., Mallinson K., Ulrich J.D., Young K.L., Robinette M.L., et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 2015, 160:1061-1071.
28. Wider C., Van Gerpen J.A., DeArmond S., Shuster E.A., Dickson D.W., Wszolek Z.K. Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD): a single entity. Neurology 2009, 72:1953-1959.
29. Chitu V., Gokhan S., Gulinello M., Branch C.A., Patil M., Basu R., et al. Phenotypic characterization of a Csf1r haploinsufficient mouse model of adult-onset leukodystrophy with axonal spheroids and pigmented glia (ALSP). Neurobiol. Dis. 2015, 74:219-228.
30. Schmid C.D., Sautkulis L.N., Danielson P.E., Cooper J., Hasel K.W., Hilbush B.S., et al. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J. Neurochem. 2002, 83:1309-1320.
31. Thrash J.C., Torbett B.E., Carson M.J. Developmental regulation of TREM2 and DAP12 expression in the murine CNS: implications for Nasu-Hakola disease. Neurochem. Res. 2009, 34:38-45.
32. Verloes A., Maquet P., Sadzot B., Vivario M., Thiry A., Franck G. Nasu-Hakola syndrome: polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia. J. Med. Genet. 1997, 34:753-757.
33. Poliani P.L., Wang Y., Fontana E., Robinette M.L., Yamanishi Y., Gilfillan S., et al. TREM2 sustains microglial expansion during aging and response to demyelination. J. Clin. Invest. 2015, 125:2161-2170.
34. Davalos D., Grutzendler J., Yang G., Kim J.V., Zuo Y., Jung S., et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 2005, 8:752-758.
35. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science (New York, NY) 2005, 308:1314-1318.
36. Erblich B., Zhu L., Etgen A.M., Dobrenis K., Pollard J.W. Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits. PLoS One 2011, 6:e26317.
37. Paolicelli R.C., Bolasco G., Pagani F., Maggi L., Scianni M., Panzanelli P., et al. Synaptic pruning by microglia is necessary for normal brain development. Science (New York, NY) 2011, 333:1456-1458.
38. Schafer D.P., Lehrman E.K., Kautzman A.G., Koyama R., Mardinly A.R., Yamasaki R., et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012, 74:691-705.
39. Parkhurst C.N., Yang G., Ninan I., Savas J.N., Yates J.R., Lafaille J.J., et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 2013, 155:1596-1609.
40. Coull J.A., Beggs S., Boudreau D., Boivin D., Tsuda M., Inoue K., et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 2005, 438:1017-1021.
41. Pascual O., Ben Achour S., Rostaing P., Triller A., Bessis A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E197-E205.
42. Tsuda M., Shigemoto-Mogami Y., Koizumi S., Mizokoshi A., Kohsaka S., Salter M.W., et al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003, 424:778-783.
43. Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 2013, 368:117-127.
44. Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 2013, 368:107-116.
45. Korvatska O., Leverenz J.B., Jayadev S., McMillan P., Kurtz I., Guo X., et al. R47H variant of TREM2 associated with Alzheimer disease in a large late-onset family: clinical, genetic, and neuropathological study. JAMA Neurol. 2015, 72:920-927.
46. Rosenthal S.L., Bamne M.N., Wang X., Berman S., Snitz B.E., Klunk W.E., et al. More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. Neurobiol. Aging 2015, 36. 2443. e2421-e2446.
47. Huang M., Wang D., Xu Z., Xu Y., Xu X., Ma Y., et al. Lack of genetic association between TREM2 and Alzheimer's disease in East Asian population: a systematic review and meta-analysis. Am. J. Alzheimers Dis. Other Dement. 2015.
48. Jiao B., Liu X., Tang B., Hou L., Zhou L., Zhang F., et al. Investigation of TREM2, PLD3, and UNC5C variants in patients with Alzheimer's disease from mainland. China Neurobiol. Aging 2014, 35. 2422. e2429-e2422. e2411.
49. Ma J., Zhou Y., Xu J., Liu X., Wang Y., Deng Y., et al. Association study of TREM2 polymorphism rs75932628 with late-onset Alzheimer's disease in Chinese Han population. Neurol. Res. 2014, 36:894-896.
50. Miyashita A., Wen Y., Kitamura N., Matsubara E., Kawarabayashi T., Shoji M., et al. Lack of genetic association between TREM2 and late-onset Alzheimer's disease in a Japanese population. J. Alzheimers Dis. 2014, 41:1031-1038.
51. Yu J.T., Jiang T., Wang Y.L., Wang H.F., Zhang W., Hu N., et al. Triggering receptor expressed on myeloid cells 2 variant is rare in late-onset Alzheimer's disease in Han Chinese individuals. Neurobiol. Aging 2014, 35. 937. e931-e933.
52. Rayaprolu S., Mullen B., Baker M., Lynch T., Finger E., Seeley W.W., et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol. Neurodegener. 2013, 8:19.
53. Lill C.M., Rengmark A., Pihlstrom L., Fogh I., Shatunov A., Sleiman P.M., et al. The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimers Dement. 2015.
54. Cady J., Koval E.D., Benitez B.A., Zaidman C., Jockel-Balsarotti J., Allred P., et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014, 71:449-453.
55. Hollingworth P., Harold D., Sims R., Gerrish A., Lambert J.C., Carrasquillo M.M., et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 2011, 43:429-435.
56. Naj A.C., Jun G., Beecham G.W., Wang L.S., Vardarajan B.N., Buros J., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 2011, 43:436-441.
57. Griciuc A., Serrano-Pozo A., Parrado A.R., Lesinski A.N., Asselin C.N., Mullin K., et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013, 78:631-643.
58. Bradshaw E.M., Chibnik L.B., Keenan B.T., Ottoboni L., Raj T., Tang A., et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat. Neurosci. 2013, 16:848-850.
59. Crehan H., Hardy J., Pocock J. Blockage of CR1 prevents activation of rodent microglia. Neurobiol. Dis. 2013, 54:139-149.
60. Brouwers N., Van Cauwenberghe C., Engelborghs S., Lambert J.C., Bettens K., Le Bastard N., et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol. Psychiatry 2012, 17:223-233.
61. Hazrati L.N., Van Cauwenberghe C., Brooks P.L., Brouwers N., Ghani M., Sato C., et al. Genetic association of CR1 with Alzheimer's disease: a tentative disease mechanism. Neurobiol. Aging 2012, 33. 2949. e2945-e2949. e2912.
62. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
63. Thakkar J.P., Dolecek T.A., Horbinski C., Ostrom Q.T., Lightner D.D., Barnholtz-Sloan J.S., et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol. Biomarkers Prev. 2014, 23:1985-1996.
64. Charles N.A., Holland E.C., Gilbertson R., Glass R., Kettenmann H. The brain tumor microenvironment. Glia 2012, 60:502-514.
65. Hussain S.F., Yang D., Suki D., Aldape K., Grimm E., Heimberger A.B. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006, 8:261-279.
66. Badie B., Schartner J.M. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 2000, 46:957-961. (discussion 961-962).
67. Coniglio S.J., Eugenin E., Dobrenis K., Stanley E.R., West B.L., Symons M.H., et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol. Med. 2012, 18:519-527.
68. Engler J.R., Robinson A.E., Smirnov I., Hodgson J.G., Berger M.S., Gupta N., et al. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One 2012, 7:e43339.
69. Komohara Y., Ohnishi K., Kuratsu J., Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 2008, 216:15-24.
70. Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19:1264-1272.
71. Xu J., Escamilla J., Mok S., David J., Priceman S., West B., et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013, 73:2782-2794.